JP6190372B2 - 抗ウイルスヌクレオチド類似体を調製する方法 - Google Patents
抗ウイルスヌクレオチド類似体を調製する方法 Download PDFInfo
- Publication number
- JP6190372B2 JP6190372B2 JP2014534535A JP2014534535A JP6190372B2 JP 6190372 B2 JP6190372 B2 JP 6190372B2 JP 2014534535 A JP2014534535 A JP 2014534535A JP 2014534535 A JP2014534535 A JP 2014534535A JP 6190372 B2 JP6190372 B2 JP 6190372B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ethyl
- acetonitrile
- propyl
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C[n]1c2ncnc(N)c2nc1)OCP(*)(Oc1ccccc1)=O Chemical compound C[C@](C[n]1c2ncnc(N)c2nc1)OCP(*)(Oc1ccccc1)=O 0.000 description 2
- HWPVJUKPFBAVRE-NEPJUHHUSA-N CC(C)OC([C@H](C)NC/C(/O)=[O]/CO[C@H](C)C[n]1c2ncnc(N)c2nc1)=O Chemical compound CC(C)OC([C@H](C)NC/C(/O)=[O]/CO[C@H](C)C[n]1c2ncnc(N)c2nc1)=O HWPVJUKPFBAVRE-NEPJUHHUSA-N 0.000 description 1
- ITAMCOCNZJPJDF-LLVKDONJSA-N C[C@H](C[n]1c2ncnc(N)c2nc1)OCP(O)(Oc1ccccc1)=O Chemical compound C[C@H](C[n]1c2ncnc(N)c2nc1)OCP(O)(Oc1ccccc1)=O ITAMCOCNZJPJDF-LLVKDONJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61/544,950 | 2011-10-07 | ||
| PCT/US2012/000441 WO2013052094A2 (en) | 2011-10-07 | 2012-10-03 | Methods for preparing anti-viral nucleotide analogs |
| US201161544950P | 2014-04-11 | 2014-04-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083047A Division JP2017160228A (ja) | 2011-10-07 | 2017-04-19 | 抗ウイルスヌクレオチド類似体を調製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530809A JP2014530809A (ja) | 2014-11-20 |
| JP2014530809A5 JP2014530809A5 (enExample) | 2015-11-19 |
| JP6190372B2 true JP6190372B2 (ja) | 2017-08-30 |
Family
ID=47297386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534535A Active JP6190372B2 (ja) | 2011-10-07 | 2012-10-03 | 抗ウイルスヌクレオチド類似体を調製する方法 |
| JP2017083047A Withdrawn JP2017160228A (ja) | 2011-10-07 | 2017-04-19 | 抗ウイルスヌクレオチド類似体を調製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083047A Withdrawn JP2017160228A (ja) | 2011-10-07 | 2017-04-19 | 抗ウイルスヌクレオチド類似体を調製する方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US8664386B2 (enExample) |
| EP (2) | EP2764002B1 (enExample) |
| JP (2) | JP6190372B2 (enExample) |
| KR (3) | KR102139440B1 (enExample) |
| CN (4) | CN107266498B (enExample) |
| AR (1) | AR088109A1 (enExample) |
| AU (3) | AU2012319172B2 (enExample) |
| BR (2) | BR112014011340A2 (enExample) |
| CA (2) | CA2850466C (enExample) |
| CL (1) | CL2014000827A1 (enExample) |
| CO (1) | CO6940431A2 (enExample) |
| CR (1) | CR20140204A (enExample) |
| EA (1) | EA027086B1 (enExample) |
| EC (1) | ECSP14000074A (enExample) |
| ES (2) | ES2746859T3 (enExample) |
| HK (1) | HK1255222B (enExample) |
| IL (1) | IL231879B (enExample) |
| MX (1) | MX353064B (enExample) |
| PE (1) | PE20141160A1 (enExample) |
| PL (1) | PL3333173T3 (enExample) |
| PT (2) | PT3333173T (enExample) |
| SI (1) | SI3333173T1 (enExample) |
| TW (4) | TWI689513B (enExample) |
| UY (1) | UY34361A (enExample) |
| WO (1) | WO2013052094A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141328A1 (es) | 2011-08-16 | 2014-10-04 | Gilead Sciences Inc | Tenofovir alafenamida hemifumarato |
| CN107266498B (zh) | 2011-10-07 | 2023-10-03 | 吉利德科学公司 | 制备抗病毒核苷酸类似物的方法 |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| ZA201404147B (en) * | 2013-06-07 | 2016-01-27 | Cipla Ltd | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
| CN104628773B (zh) * | 2013-11-06 | 2018-10-23 | 杭州和泽医药科技有限公司 | (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法 |
| IN2013CH05455A (enExample) * | 2013-11-27 | 2015-08-07 | Laurus Labs Private Ltd | |
| IN2014MU00118A (enExample) * | 2014-01-14 | 2015-08-28 | Mylan Lab Ltd | |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| WO2015161785A1 (zh) * | 2014-04-21 | 2015-10-29 | 四川海思科制药有限公司 | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 |
| WO2015197006A1 (zh) * | 2014-06-25 | 2015-12-30 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
| CN105399771B (zh) * | 2014-07-21 | 2020-11-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药晶型及其制备方法和用途 |
| CN105646584B (zh) * | 2014-11-12 | 2018-09-28 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途 |
| CN104817593B (zh) * | 2015-04-27 | 2016-11-16 | 广州同隽医药科技有限公司 | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 |
| CN113461733A (zh) | 2015-08-05 | 2021-10-01 | 卫材R&D管理有限公司 | 用于制备均一低聚物的手性试剂 |
| TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
| CN105330700A (zh) * | 2015-12-17 | 2016-02-17 | 中国药科大学 | 富马酸替诺福韦艾拉酚胺杂质的制备方法 |
| WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
| CZ2016156A3 (cs) * | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
| CN107286190A (zh) * | 2016-04-13 | 2017-10-24 | 刘沛 | 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
| CN106946935B (zh) * | 2017-04-28 | 2020-01-07 | 福建广生堂药业股份有限公司 | 一种非对映异构体核苷衍生物的制备方法 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019070827A1 (en) * | 2017-10-04 | 2019-04-11 | Celgene Corporation | PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide |
| CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN110092803A (zh) * | 2018-01-31 | 2019-08-06 | 北京睿创康泰医药研究院有限公司 | 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用 |
| CN108409788B (zh) * | 2018-03-12 | 2020-05-08 | 科兴生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺的制备方法 |
| CN110305163A (zh) * | 2018-03-27 | 2019-10-08 | 北京济美堂医药研究有限公司 | 替诺福韦艾拉酚胺半富马酸盐的制备方法 |
| CN108467410B (zh) * | 2018-04-09 | 2021-04-09 | 重庆三圣实业股份有限公司 | 一种taf中间体的制备方法及产品和应用 |
| CN108484672A (zh) * | 2018-05-23 | 2018-09-04 | 中国药科大学制药有限公司 | 磷丙替诺福韦的手性拆分方法 |
| CN108822149B (zh) * | 2018-06-01 | 2020-08-11 | 成都苑东生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法 |
| CN110283208B (zh) * | 2018-06-22 | 2022-07-08 | 南京济群医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的手性拆分方法 |
| CN109081853A (zh) * | 2018-09-03 | 2018-12-25 | 南京正大天晴制药有限公司 | 一种磷丙替诺福韦有关物质的制备方法 |
| CN111484527A (zh) * | 2019-01-25 | 2020-08-04 | 上海清松制药有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| CN111943981A (zh) * | 2019-05-14 | 2020-11-17 | 博瑞生物医药泰兴市有限公司 | 一种磷丙替诺福韦的制备方法 |
| CN112175003B (zh) * | 2019-07-01 | 2022-02-15 | 上海医药工业研究院 | 一种苯基氢膦酸酯及其中间体的制备方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112390824B (zh) * | 2019-08-19 | 2022-07-05 | 鲁南制药集团股份有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| CN110981911A (zh) * | 2019-10-08 | 2020-04-10 | 浙江车头制药股份有限公司 | 一种替诺福韦艾拉酚胺的制备方法 |
| CN111171076A (zh) * | 2019-12-26 | 2020-05-19 | 合肥启旸生物科技有限公司 | 一种替诺福韦二聚体的制备方法 |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
| WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| KR20220141457A (ko) | 2021-04-13 | 2022-10-20 | 경동제약 주식회사 | 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물 |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202434566A (zh) | 2022-07-01 | 2024-09-01 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| WO2024249592A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Quinazolinyl-indazole derivatives as therapeutic compounds for hiv |
| TW202504592A (zh) | 2023-05-31 | 2025-02-01 | 美商基利科學股份有限公司 | 固體形式 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03000587A (es) * | 2000-07-21 | 2004-04-05 | Gilead Sciences Inc | Profarmacos de analogos de nucleotido de fosfonato y metodos para seleccionar y elaborar los mismos. |
| US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| AU2005330489B2 (en) * | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| WO2007126812A2 (en) | 2006-03-29 | 2007-11-08 | Gilead Sciences, Inc. | Process for preparation of hiv protease inhibitors |
| WO2008005555A1 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| NZ573888A (en) * | 2006-07-21 | 2012-02-24 | Gilead Sciences Inc | Aza-peptide protease inhibitors |
| KR20090040449A (ko) * | 2006-07-24 | 2009-04-24 | 길리애드 사이언시즈, 인코포레이티드 | 신규 ｈｉｖ 역전사 효소 억제제 |
| US8354421B2 (en) * | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
| PE20141328A1 (es) | 2011-08-16 | 2014-10-04 | Gilead Sciences Inc | Tenofovir alafenamida hemifumarato |
| CN107266498B (zh) | 2011-10-07 | 2023-10-03 | 吉利德科学公司 | 制备抗病毒核苷酸类似物的方法 |
-
2012
- 2012-10-03 CN CN201710365515.5A patent/CN107266498B/zh active Active
- 2012-10-03 PT PT18153951T patent/PT3333173T/pt unknown
- 2012-10-03 UY UY34361A patent/UY34361A/es not_active Application Discontinuation
- 2012-10-03 AU AU2012319172A patent/AU2012319172B2/en active Active
- 2012-10-03 MX MX2014003952A patent/MX353064B/es active IP Right Grant
- 2012-10-03 PT PT127980290T patent/PT2764002T/pt unknown
- 2012-10-03 TW TW106145797A patent/TWI689513B/zh active
- 2012-10-03 ES ES18153951T patent/ES2746859T3/es active Active
- 2012-10-03 EP EP12798029.0A patent/EP2764002B1/en active Active
- 2012-10-03 TW TW108139308A patent/TWI709567B/zh active
- 2012-10-03 PL PL18153951T patent/PL3333173T3/pl unknown
- 2012-10-03 TW TW105126598A patent/TWI613211B/zh active
- 2012-10-03 US US13/573,666 patent/US8664386B2/en active Active
- 2012-10-03 CN CN201280048965.7A patent/CN103842366B/zh active Active
- 2012-10-03 KR KR1020197019875A patent/KR102139440B1/ko active Active
- 2012-10-03 CN CN202311252160.0A patent/CN117343101A/zh active Pending
- 2012-10-03 BR BR112014011340A patent/BR112014011340A2/pt unknown
- 2012-10-03 WO PCT/US2012/000441 patent/WO2013052094A2/en not_active Ceased
- 2012-10-03 JP JP2014534535A patent/JP6190372B2/ja active Active
- 2012-10-03 EP EP18153951.1A patent/EP3333173B1/en active Active
- 2012-10-03 KR KR1020147011619A patent/KR102033802B1/ko active Active
- 2012-10-03 KR KR1020207021316A patent/KR20200090975A/ko not_active Withdrawn
- 2012-10-03 TW TW101136508A patent/TWI557133B/zh active
- 2012-10-03 PE PE2014000495A patent/PE20141160A1/es not_active Application Discontinuation
- 2012-10-03 CN CN202110408116.9A patent/CN113264959A/zh active Pending
- 2012-10-03 CA CA2850466A patent/CA2850466C/en active Active
- 2012-10-03 CA CA3042169A patent/CA3042169C/en active Active
- 2012-10-03 AR ARP120103681 patent/AR088109A1/es not_active Application Discontinuation
- 2012-10-03 ES ES12798029.0T patent/ES2661705T3/es active Active
- 2012-10-03 SI SI201231626T patent/SI3333173T1/sl unknown
- 2012-10-03 EA EA201490753A patent/EA027086B1/ru unknown
-
2014
- 2014-01-14 US US14/154,313 patent/US9029534B2/en active Active
- 2014-04-02 IL IL23187914A patent/IL231879B/en active IP Right Grant
- 2014-04-03 CL CL2014000827A patent/CL2014000827A1/es unknown
- 2014-04-11 BR BR102014008928-4A patent/BR102014008928B1/pt active IP Right Grant
- 2014-05-02 CO CO14093468A patent/CO6940431A2/es active IP Right Grant
- 2014-05-05 EC ECIEPI201474A patent/ECSP14000074A/es unknown
- 2014-05-05 CR CR20140204A patent/CR20140204A/es unknown
- 2014-08-21 AU AU2014215976A patent/AU2014215976B2/en active Active
-
2015
- 2015-02-06 HK HK18114351.4A patent/HK1255222B/en unknown
- 2015-04-08 US US14/681,955 patent/US9346841B2/en active Active
-
2016
- 2016-04-21 US US15/135,357 patent/US9676804B2/en active Active
- 2016-09-19 AU AU2016228317A patent/AU2016228317B2/en active Active
-
2017
- 2017-04-19 JP JP2017083047A patent/JP2017160228A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6190372B2 (ja) | 抗ウイルスヌクレオチド類似体を調製する方法 | |
| HK1255222A1 (en) | Methods for preparing anti-viral nucleotide analogs | |
| HK40052309A (en) | Methods for preparing anti-viral nucleotide analogs | |
| HK1200834B (en) | Methods for preparing anti-viral nucleotide analogs | |
| HK1245798B (zh) | 制备抗病毒核苷酸类似物的方法 | |
| NZ624513B2 (en) | Methods for preparing anti-viral nucleotide analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160907 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170419 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170623 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170712 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170804 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6190372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |